Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial.

Stephan Kadauke Regina M Myers Yimei Li Richard AplencDiane BaniewiczDavid M BarrettAllison Barz LeahyColleen CallahanJ Gregory DolanJulie C FitzgeraldWhitney GladneySimon F LaceyHongyan LiuShannon L MaudeRegina McGuireLaura S MotleyDavid Trent TeacheyGerald B WertheimLisa WrayAmanda M DiNofiaStephan A Grupp

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)

Risk-adapted PT administration resulted in a decrease in the expected incidence of grade 4 CRS, meeting the study end point, without adversely impacting the antitumor efficacy or safety of CTL019.

Keyphrases

acute lymphoblastic leukemia
clinical trial
rheumatoid arthritis
risk factors
randomized controlled trial
case report
allogeneic hematopoietic stem cell transplantation
systemic lupus erythematosus
study protocol
juvenile idiopathic arthritis
disease activity